Medidata Needs Faster Revenue Growth To Justify Lofty Stock Price
- Medidata's revenue growth seems maxed out in the mid-20% and carries increased costs.
- Medidata's stock price is still trading above valuations of merger and acquisitions in cloud software after years of rapid multiple expansion.
- Potential for 30% downside from current trading levels if revenue growth doesn't improve.
- Musings on "cloud" branding in investor materials and a dubious stock split.